Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) EVP Zachary Roberts sold 27,199 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the sale, the executive vice president now directly owns 488,054 shares of the company's stock, valued at $868,736.12. The trade was a 5.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
ALLO traded down $0.04 during trading on Thursday, reaching $1.88. The company had a trading volume of 1,389,630 shares, compared to its average volume of 2,946,952. The firm's 50-day simple moving average is $2.14 and its 200 day simple moving average is $2.52. Allogene Therapeutics, Inc. has a 12-month low of $1.78 and a 12-month high of $5.78. The company has a market cap of $394.18 million, a price-to-earnings ratio of -1.21 and a beta of 0.86.
Several brokerages have weighed in on ALLO. Piper Sandler decreased their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, November 14th. HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a report on Friday, November 8th. Finally, William Blair restated an "outperform" rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, Allogene Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $9.73.
Check Out Our Latest Stock Report on Allogene Therapeutics
Several hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC bought a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at approximately $6,349,000. Lynx1 Capital Management LP acquired a new position in shares of Allogene Therapeutics during the 2nd quarter worth $5,192,000. Renaissance Technologies LLC raised its holdings in shares of Allogene Therapeutics by 340.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company's stock valued at $4,073,000 after purchasing an additional 1,351,055 shares in the last quarter. Zacks Investment Management bought a new position in shares of Allogene Therapeutics during the 3rd quarter valued at $1,446,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company's stock valued at $5,944,000 after purchasing an additional 507,021 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Allogene Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.
While Allogene Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.